View ValuationNeurizon Therapeutics 将来の成長Future 基準チェック /06現在、 Neurizon Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長18.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 17Neurizon Therapeutics Limited Completes Enrollment In Regimen I Of The Phase 2/3 HEALEY ALS Platform Trial Evaluating NUZ-001 For The Treatment Of Amyotrophic Lateral SclerosisNeurizon Therapeutics Limited advised that enrolment has been completed in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating the Company's lead investigational therapy NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS). Neurizon advised that the final participant has completed their baseline visit and commenced treatment, completing enrolment into Regimen I. The Company now expects to report topline efficacy and safety results in late Second Quarter Calendar Year 2027, earlier than previously anticipated. Completion of enrolment, together with the earlier anticipated timing of the topline results readout, further demonstrates the continued advancement of the late-stage clinical development program for NUZ-001 for the treatment of ALS. Regimen I completed enrolment in less than five months from first participant dosing, becoming the fastest regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial, even after the planned sample size expansion from 160 to 240 participants in response to strong recruitment momentum. This achievement reflects the strength of recruitment across the HEALEY ALS Platform Trial network, one of the world's leading ALS clinical trial initiatives, the operational efficiencies introduced under the trial's next generation master protocol, and the commitment of investigators, research coordinators and clinical site teams across the United States. Participants will now continue through the 36-week Randomised Controlled Trial phase before entering the 36-week Active Treatment Extension phase, with the Company's focus centred on continued execution ahead of the anticipated topline readout in late Second Quarter Calendar Year 2027. The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States, created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.お知らせ • Mar 19Neurizon Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.106469 million.Neurizon Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.106469 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 79,330,864 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Feb 27Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform TrialNeurizon®? Therapeutics Limited announced that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS). The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEy ALS Platform Trial is to accelerate the development of potential new ALS therapies. The trial evaluate multiple investigational drugs (Regimens) concurrently under a single framework or master protocol, leveraging shared infrastructure across over 70 participating clinical sites. By streamlining start-up and enrollment processes, it accelerates study execution and delivers results more efficiently. Regimen I (NUZ-001) includes a randomised, placebo-controlled treatment (RCT) phase followed by an active treatment extension (ATE) phase, both with a 36-week treatment period. Approximately 160 participants with ALS will be randomised to receive either daily NUZ-001 at the recommended Phase 2 dose of 10 mg/kg or placebo at a 3:1 ratio. The primary objective is to evaluate the efficacy of NUZ-001 compared with placebo on ALS disease progression, with secondary objectives including additional measures of disease progression and safety. Participation in the HEALEY ALS platform Trial provides Neurizon with access to an established clinical development framework supported by the world's most highly regarded ALS investigators and leading clinical centres across the US. This infrastructure improves trial efficiency, supports consistent data generation and facilitates ongoing engagement with regulatory authorities, including the U.S. Food and Drug Administration (FDA), as the trial progresses.お知らせ • Dec 24Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 17.145251 million.Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 17.145251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 214,315,640 Price\Range: AUD 0.08 Transaction Features: Rights Offeringお知らせ • Dec 23Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7.126469 million.Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7.126469 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,080,864 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Neurizon Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NUZT.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20256-15-17-17N/A9/30/20254-16-16-16N/A6/30/20252-17-14-14N/A3/31/20252-16-12-12N/A12/31/20242-15-10-10N/A9/30/20241-12-8-8N/A6/30/20241-9-5-5N/A3/31/20241-6-3-3N/A12/31/20231-3-2-2N/A9/30/20231-2-2-2N/A6/30/20231-2-2-2N/A3/31/20232-1-1-1N/A12/31/20224-100N/A9/30/20224-1-1-1N/A6/30/20225-2-1-1N/A3/31/20224-2-1-1N/A12/31/20214-2-2-1N/A9/30/20214-2-1-1N/A6/30/20214-1-1-1N/A3/31/20214-2-1-1N/A12/31/20203-200N/A9/30/20204-2-1-1N/A6/30/20204-1-1-1N/A3/31/20204-2-2-2N/A12/31/20194-2-2-2N/A9/30/20194-2N/A-2N/A6/30/20194-2N/A-2N/A3/31/20194-1N/A-1N/A12/31/20184-1N/A-1N/A9/30/20184-2N/A-1N/A6/30/20183-3N/A-2N/A3/31/20183-2N/A-2N/A12/31/20173-2N/A-2N/A9/30/20173-2N/A-1N/A6/30/20173-1N/A-1N/A3/31/20173-2N/A-1N/A12/31/20163-3N/A-1N/A9/30/20163-4N/A-1N/A6/30/20163-4N/A-2N/A3/31/20163-3N/A-2N/A12/31/20153-2N/A-2N/A9/30/20153-2N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NUZT.Fの予測収益成長が 貯蓄率 ( 3.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NUZT.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NUZT.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NUZT.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NUZT.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NUZT.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 18:51終値2026/06/29 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neurizon Therapeutics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 17Neurizon Therapeutics Limited Completes Enrollment In Regimen I Of The Phase 2/3 HEALEY ALS Platform Trial Evaluating NUZ-001 For The Treatment Of Amyotrophic Lateral SclerosisNeurizon Therapeutics Limited advised that enrolment has been completed in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating the Company's lead investigational therapy NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS). Neurizon advised that the final participant has completed their baseline visit and commenced treatment, completing enrolment into Regimen I. The Company now expects to report topline efficacy and safety results in late Second Quarter Calendar Year 2027, earlier than previously anticipated. Completion of enrolment, together with the earlier anticipated timing of the topline results readout, further demonstrates the continued advancement of the late-stage clinical development program for NUZ-001 for the treatment of ALS. Regimen I completed enrolment in less than five months from first participant dosing, becoming the fastest regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial, even after the planned sample size expansion from 160 to 240 participants in response to strong recruitment momentum. This achievement reflects the strength of recruitment across the HEALEY ALS Platform Trial network, one of the world's leading ALS clinical trial initiatives, the operational efficiencies introduced under the trial's next generation master protocol, and the commitment of investigators, research coordinators and clinical site teams across the United States. Participants will now continue through the 36-week Randomised Controlled Trial phase before entering the 36-week Active Treatment Extension phase, with the Company's focus centred on continued execution ahead of the anticipated topline readout in late Second Quarter Calendar Year 2027. The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States, created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
お知らせ • Mar 19Neurizon Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.106469 million.Neurizon Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.106469 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 79,330,864 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 27Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform TrialNeurizon®? Therapeutics Limited announced that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS). The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEy ALS Platform Trial is to accelerate the development of potential new ALS therapies. The trial evaluate multiple investigational drugs (Regimens) concurrently under a single framework or master protocol, leveraging shared infrastructure across over 70 participating clinical sites. By streamlining start-up and enrollment processes, it accelerates study execution and delivers results more efficiently. Regimen I (NUZ-001) includes a randomised, placebo-controlled treatment (RCT) phase followed by an active treatment extension (ATE) phase, both with a 36-week treatment period. Approximately 160 participants with ALS will be randomised to receive either daily NUZ-001 at the recommended Phase 2 dose of 10 mg/kg or placebo at a 3:1 ratio. The primary objective is to evaluate the efficacy of NUZ-001 compared with placebo on ALS disease progression, with secondary objectives including additional measures of disease progression and safety. Participation in the HEALEY ALS platform Trial provides Neurizon with access to an established clinical development framework supported by the world's most highly regarded ALS investigators and leading clinical centres across the US. This infrastructure improves trial efficiency, supports consistent data generation and facilitates ongoing engagement with regulatory authorities, including the U.S. Food and Drug Administration (FDA), as the trial progresses.
お知らせ • Dec 24Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 17.145251 million.Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 17.145251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 214,315,640 Price\Range: AUD 0.08 Transaction Features: Rights Offering
お知らせ • Dec 23Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7.126469 million.Neurizon Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7.126469 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,080,864 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing